Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
New breast cancer therapy study findings have been reported by scientists at University of Texas, M.D. Anderson Cancer Center
February 1st, 2007
Scientists discuss in "Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen" new findings in breast cancer. According to recent research from the United States, "Findings from our previously published phase III randomized trial showed a high pathologic complete remission (CR) rate in patients with human epidermal growth factor receptor 2-positive breast cancer after the concurrent administration of trastuzumab and...
Source: Women's Health Weekly (2007-02-01)
|
|
Advertisement |
|
|
|
